Estrogen and progestin components of oral contraceptives: Relationship to vascular disease

Contraception

Volumn 55, Issue 5, 1997, Pages 267-272

  Carr, Bruce R ^a,b   Ory, Howard ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE

Author keywords

Coagulation system; Myocardial infarction; Oral contraception; Smoking; Stroke; Venous thromboembolism

Indexed keywords

DESOGESTREL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GESTODENE; LEVONORGESTREL; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

CIGARETTE SMOKING; CLINICAL TRIAL; DRUG FORMULATION; FEMALE; HEART INFARCTION; HUMAN; ORAL CONTRACEPTION; REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; VASCULAR DISEASE;

BIOLOGY; BLOOD COAGULATION EFFECTS; CARDIOVASCULAR EFFECTS; CONTRACEPTION; CONTRACEPTIVE METHODS--PHARMACODYNAMICS; DISEASES; EMBOLISM; EVALUATION; FAMILY PLANNING; HEART DISEASES; HEMATOLOGICAL EFFECTS; HEMIC SYSTEM; LITERATURE REVIEW; MYOCARDIAL INFARCTION; ORAL CONTRACEPTIVES, COMBINED--PHARMACODYNAMICS; ORAL CONTRACEPTIVES--PHARMACODYNAMICS; PHYSIOLOGY; RISK ASSESSMENT; THROMBOEMBOLISM; VASCULAR DISEASES;

CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CONTRACEPTIVES, ORAL; ESTROGENS; FEMALE; HUMANS; MYOCARDIAL INFARCTION; PROGESTINS; RISK FACTORS; SMOKING;

EID: 0030750316     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00029-2     Document Type: Review

References (36)

1. Mishell DR, Jr. Oral contraception: past, present, and future perspectives. Int J Fertil 1991;36:(suppl)7-18.
2. Speroff L, DeCherney A, and The Advisory Board for the New Progestins. Evaluation of a new generation of oral contraceptives. Obstet Gynecol 1993;81:1034-47.
3. Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content. Lancet 1980;i:1097-101.
4. Meade TW, Greenberg G, Thompson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-μg oestrogen preparations. BMJ 1980;280:1157-61.
5. Mann JI. Progestogens in cardiovascular disease: an introduction to the epidemiologic data. Am J Obstet Gynecol 1982;142:752-7.
6. Croft P, Hannaford PC. Risk factors for acute myocardial infarction in women: evidence from the Royal College of General Practitioners' oral contraception study. BMJ 1989;298:165-8.
7. Rosenberg L, Palmer JR, Lesko SM, Shapiro S. Oral contraceptive use and the risk of myocardial infarction. Am J Epidemiol 1990;131:1009-16.
8. Thorogood M, Mann J, Murphy M, Vessey M. Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Report of a case-control study. Br J Obstet Gynecol 1991;98:1245-53.
9. Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;317: 1303-9.
10. Sidney S, Pettiti DB, Quesenberry CP Jr, Klatsky AL, Ziel HK, Wolf S. Myocardial infarction in users of low-dose oral contraceptives. Obstet Gynecol 1996;88: 939-44.
11. Jick H, Jick SS, Myers MW, Vasilakis C. Risk of acute myocardial infarction and low-dose combined oral contraceptives [letter]. Lancet 1996;347:627-8.
12. Wolf PA, Cobb JL, D'Agostino RB. Epidemiology of stroke. In: Barnett HJM, Stein BM, Mohr JP, Yatsu FM, eds. Stroke: pathophysiology, diagnosis, and management. New York: Churchill Livingstone, 1992:3-27.
13. Vessey MP, Lawless M, Yeates D. Oral contraceptives and stroke: findings in a large prospective study. BMJ 1984;289:530-1.
14. Hannaford PC, Croft PR, Kay CR. Oral contraception and stroke: evidence from the Royal College of General Practitioners' oral contraception study. Stroke 1994;25: 935-42.
15. Lidegaard Ø. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ 1993;306:956-63.
16. Petitti DB, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel HK. Stroke in users of low-dose oral contraceptives. N Engl J Med 1996;335:8-15.
17. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Ischemic stroke and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996; 348:498-505.
18. Longstreth WT, Nelson LM, Koepsell TD, van Belle G. Subarachnoid hemorrhage and hormonal factors in women: a population-based case-control study. Ann Intern Med 1994;121:168-73.
19. Thorogood M, Mann J, Murphy M, Vessey M. Fatal stroke and use of oral contraceptives: findings from a case-control study. Am J Epidemiol 1992;136:35-45.
20. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Hemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study. Lancet 1996;348:505-10.
21. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82.
22. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992;21:48-52.
23. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.
24. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ 1986;292:526.
25. Porter JB, Hunter JR, Jick H, Stergachis A. Oral contraceptives and nonfatal vascular disease. Obstet Gynecol 1985;66:1-4.
26. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995;346:1582-8.
27. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestogen components. Lancet 1995;346;1589-93.
28. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD on behalf of Transnational Research Group on Oral Contraceptives and the Health of Young Women. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996;312:83-8.
29. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
30. Helmrich SP, Rosenberg L, Kaufman DW, Strom B, Shapiro S. Venous thromboembolism in relation to oral contraceptive use. Obstet Gynecol 1987;69:91-5.
31. Hirvonen E, Idänpään-Heikkilä J. Cardiovascular death among women under 40 years of age using low-estrogen dose oral contraceptives and intrauterine devices in Finland from 1975 to 1984. Am J Obstet Gynecol 1990;163:281-4.
32. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by Factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestogen. Lancet 1995;346:1593-6.
33. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO, with the Transnational Research Group on Oral Contraceptives and the Health of Young Women. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996;54:5-13.
34. Oral contraceptives and venous thromboembolism: consensus conference statement. Dialogues in Contraception 1996;Spring:1-8.
35. Jamin C, de Mouzon J. Selective prescribing of third generation oral contraceptives (OCs). Contraception 1996;54:55-6.
36. Cigarette smoking among women of reproductive age -United States, 1987-1992. MMWR 1994;43:789-91, 797.